N. Lynn Henry

1.5k total citations · 1 hit paper
43 papers, 1.1k citations indexed

About

N. Lynn Henry is a scholar working on Oncology, Genetics and Cancer Research. According to data from OpenAlex, N. Lynn Henry has authored 43 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 15 papers in Genetics and 10 papers in Cancer Research. Recurrent topics in N. Lynn Henry's work include Cancer Treatment and Pharmacology (14 papers), Estrogen and related hormone effects (13 papers) and Breast Cancer Treatment Studies (8 papers). N. Lynn Henry is often cited by papers focused on Cancer Treatment and Pharmacology (14 papers), Estrogen and related hormone effects (13 papers) and Breast Cancer Treatment Studies (8 papers). N. Lynn Henry collaborates with scholars based in United States, United Kingdom and France. N. Lynn Henry's co-authors include Khaled A. Hassan, April Davis, Shawn G. Clouthier, Max S. Wicha, Ahmed A. Quraishi, Tahra Luther, Nader Tawakkol, Rosemarie C. D'Angelo, Hayley J. Paholak and Susan Chung and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

N. Lynn Henry

37 papers receiving 1.1k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population

2012 427 citations Hasan Körkaya, April Davis et al. Molecular Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
N. Lynn Henry United States	13	704	302	289	185	147	43	1.1k
William A. Hammond United States	8	663 0.9×	297 1.0×	184 0.6×	182 1.0×	119 0.8×	17	1.1k
Sang‐Hyun Song South Korea	26	382 0.5×	938 3.1×	187 0.6×	87 0.5×	177 1.2×	79	1.7k
Christina Hackl Germany	21	442 0.6×	492 1.6×	216 0.7×	111 0.6×	152 1.0×	48	1.3k
Ali Moshfegh Sweden	21	524 0.7×	755 2.5×	226 0.8×	304 1.6×	153 1.0×	60	1.4k
Jean Harb France	19	248 0.4×	482 1.6×	96 0.3×	175 0.9×	97 0.7×	55	1.2k
Alice Chin United States	14	223 0.3×	426 1.4×	128 0.4×	362 2.0×	109 0.7×	24	1.1k
Houda Alachkar United States	20	192 0.3×	613 2.0×	156 0.5×	236 1.3×	55 0.4×	60	1.0k
Christa Pfeifhofer‐Obermair Austria	19	295 0.4×	433 1.4×	196 0.7×	504 2.7×	69 0.5×	31	1.1k
Patrizia Pellegrini Italy	15	366 0.5×	292 1.0×	176 0.6×	405 2.2×	53 0.4×	51	968
Sergey Orlov Russia	21	867 1.2×	804 2.7×	293 1.0×	181 1.0×	1.0k 7.1×	149	2.0k

Countries citing papers authored by N. Lynn Henry

Since Specialization

Citations

This map shows the geographic impact of N. Lynn Henry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Lynn Henry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Lynn Henry more than expected).

Fields of papers citing papers by N. Lynn Henry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Lynn Henry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Lynn Henry. The network helps show where N. Lynn Henry may publish in the future.

Co-authorship network of co-authors of N. Lynn Henry

This figure shows the co-authorship network connecting the top 25 collaborators of N. Lynn Henry. A scholar is included among the top collaborators of N. Lynn Henry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Lynn Henry. N. Lynn Henry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Safgren, Stephanie L., Vera J. Suman, Roberto A. Leon Ferre, et al.. (2025). The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen. Breast Cancer Research and Treatment. 211(1). 261–270.

Lee, Kimberley, Bo Hu, Dinorah Martinez Tyson, et al.. (2025). A mixed-methods study characterizing experiences of medical oncologists’ use of gonadotropin-releasing hormone agonists for treatment of breast cancer. Breast Cancer Research and Treatment. 212(3). 449–455.

Vaidya, Riha, Cathee Till, N. Lynn Henry, et al.. (2024). Neighborhood socioeconomic deprivation and patient-reported outcomes in symptom management trials for women with breast cancer. Breast Cancer Research and Treatment. 209(3). 603–611.

Johnson, Ken B., N. Lynn Henry, Mei Wei, et al.. (2023). Genetic variations that influence paclitaxel pharmacokinetics and intracellular effects that may contribute to chemotherapy-induced neuropathy: A narrative review. SHILAP Revista de lepidopterología. 4. 1139883–1139883. 4 indexed citations

Zirpoli, Gary, William E. Barlow, G. Thomas Budd, et al.. (2023). Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221. Journal of the National Comprehensive Cancer Network. 21(11). 1172–1180.e3. 15 indexed citations

Soellner, Matthew B., et al.. (2019). Abstract PD9-12: Integrative molecular profiling of breast cancer brain metastasis and patient-derived xenograft organoids from resected breast cancer brain metastases to interrogate and prioritize therapeutic personalized strategies. Cancer Research. 79(4_Supplement). PD9–12.

Sun, Yihan, Daniel F. Hayes, Elizabeth Smith, et al.. (2018). Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy. Breast Cancer Research and Treatment. 171(3). 657–666. 29 indexed citations

Pusztai, Lajos, PA Ganz, N. Lynn Henry, et al.. (2018). Abstract OT1-02-04: SWOG S1418/NRG -BR006: A randomized, phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with > 1 cm residual invasive cancer or positive lymph nodes (>pN1mic) after neoadjuvant chemotherapy. Cancer Research. 78(4_Supplement). OT1–2. 21 indexed citations

Henry, N. Lynn, Kelly Speth, Anneleen Lintermans, et al.. (2017). Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation. Clinical Breast Cancer. 17(5). 350–355.e4. 11 indexed citations

10.

Tanioka, Maki, Chuanwen Fan, LA Carey, et al.. (2017). Abstract S3-05: Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer. Cancer Research. 77(4_Supplement). S3–5. 1 indexed citations

11.

Paoletti, Costanza, Maria C. Muñiz, Dafydd G. Thomas, et al.. (2014). Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptor–Positive Breast Cancer. Clinical Cancer Research. 21(11). 2487–2498. 104 indexed citations

12.

Skaar, Todd C., Steffi Oesterreich, Anne Nguyen, et al.. (2013). Abstract P1-08-11: Association of variants in candidate genes on lipid profiles in women with early breast cancer on adjuvant aromatase inhibitor therapy. Cancer Research. 73(24_Supplement). P1–8. 1 indexed citations

13.

Körkaya, Hasan, April Davis, Fayaz Malik, et al.. (2012). Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population. Molecular Cell. 47(4). 570–584. 427 indexed citations breakdown →

14.

Philips, Santosh, James M. Rae, Steffi Oesterreich, et al.. (2012). Whole Genome Amplification of DNA for Genotyping Pharmacogenetics Candidate Genes. Frontiers in Pharmacology. 3. 54–54. 1 indexed citations

15.

Henry, N. Lynn, Mousumi Banerjee, Max Wicha, et al.. (2011). Pilot study of duloxetine for treatment of aromatase inhibitor‐associated musculoskeletal symptoms. Cancer. 117(24). 5469–5475. 51 indexed citations

16.

Hayes, Daniel F., Todd C. Skaar, James M. Rae, et al.. (2010). Estrogen Receptor Genotypes, Menopausal Status, and the Effects of Tamoxifen on Lipid Levels: Revised and Updated Results. Clinical Pharmacology & Therapeutics. 88(5). 626–629. 12 indexed citations

17.

Henry, N. Lynn, et al.. (2010). Abstract PD08-06: Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Syndrome (AIMSS). Cancer Research. 70(24_Supplement). PD08–6.

18.

Henry, N. Lynn, Rodney L. Dunn, Quintin Pan, et al.. (2006). Phase II Trial of Copper Depletion with Tetrathiomolybdate as an Antiangiogenesis Strategy in Patients with Hormone-Refractory Prostate Cancer. Oncology. 71(3-4). 168–175. 68 indexed citations

19.

Cutler, Corey, N. Lynn Henry, Ciara N. Magee, et al.. (2005). Sirolimus and thrombotic microangiopathy after allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation. 11(2). 4–4. 1 indexed citations

20.

Cutler, Corey, N. Lynn Henry, Colm Magee, et al.. (2005). Sirolimus and Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 11(7). 551–557. 113 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact